This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen.
INTRODUCTION
Prostate cancer is the second most common cancer in men worldwide (estimated incidence of 25.3 per 100,000). 1 Docetaxel was approved by the US Food and Drug Administration as first-line therapy for castrate-refractory prostate cancer (CRPC) in 2004 and is now the standard of care. Results of two large phase III trials demonstrated an approximately 2-to 3-month median survival advantage of docetaxel-based chemotherapy compared with mitoxantrone in CRPC patients. [2] [3] [4] However, all patients eventually discontinue docetaxel because of disease progression or toxicity. 5 Patients with metastatic CRPC in whom initial chemotherapy failed have a short life expectancy; no treatments have significantly improved progression-free survival (PFS) or overall survival (OS). [6] [7] [8] Thus, an unmet need exists for an effective and well-tolerated treatment for patients with CRPC who experience progression after initial chemotherapy.
Satraplatin (bisacetato-ammine-dichlorocyclohexylamine platinum IV; JM-216), a novel oral platinum compound, has preclinical activity in prostate cancer and tumor cell lines resistant to cisplatin, taxanes, or anthracyclines. [9] [10] [11] [12] Satraplatin forms platinum-DNA adducts and cross links 13 but is not susceptible to some cisplatin resistance mechanisms.
In a phase II trial, satraplatin demonstrated activity in CRPC; myelosuppression was the dose-limiting toxicity. 15 In a randomized phase III trial of satraplatin plus prednisone versus prednisone alone as first-line therapy for patients with metastatic CRPC (terminated prematurely after 50 patients were enrolled), a significant increase in PFS (5.2 v 2.5 months, respectively; P ϭ .02; hazard ratio [HR] ϭ 0.50) was observed. The 3-month increase in median OS was not statistically significant, perhaps because of the small sample size. 16 To determine efficacy and tolerability of satraplatin in men with metastatic CRPC who experienced progression after one prior chemotherapy regimen, the Satraplatin and Prednisone Against Refractory Cancer (SPARC) randomized phase III trial was conducted.
PATIENTS AND METHODS

Patients
Men had to have stage D2 (TxNxM1) metastatic adenocarcinoma of the prostate and disease progression after two or more cycles of one prior chemotherapy regimen. Disease progression with prior chemotherapy was based on radiographic evidence of tumor progression or increasing prostate-specific antigen (PSA). Other inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status (PS) Յ 2; life expectancy more than 3 months; surgical or medical castration (serum testosterone Ͻ 50 ng/dL); and adequate bone marrow, hepatic, and renal functions (Appendix, online only). Prior bisphosphonate therapy was acceptable if bone symptoms were stabilized and therapy continued during the trial. Exclusion criteria included more than one prior chemotherapy regimen, prior platinum therapy, additional malignancy, or significant radiotherapy.
Study Design
This multinational, double-blind, randomized, placebo-controlled, phase III trial was conducted according to the Declaration of Helsinki and in compliance with Good Clinical Practice (Appendix). All patients provided written informed consent.
Patients were assigned to treatment using the following stratification variables: baseline ECOG PS (0 to 1 v 2), mean baseline Present Pain Intensity (PPI) score 17 (0 to 1 v 2 to 5), and type of disease progression after prior chemotherapy (tumor progression or PSA increase only; patients with both were considered as having tumor progression). Prespecified prognostic factors (not used for stratification) included lactate dehydrogenase (LDH), hemoglobin, alkaline phosphatase (ALP), age, racial subgroup, geography, prior docetaxel therapy, and concurrent bisphosphonate use. Patients were randomized 2:1 (stratified permutated block random assignment list with block size of six) to receive satraplatin plus prednisone or placebo plus prednisone.
Treatment Regimen
Satraplatin 80 mg/m 2 or placebo was administered orally (PO) once daily (fasting) on days 1 to 5 every 35 days. Prednisone (prednisolone) 5 mg PO was administered twice daily. Antiemetic prophylaxis (granisetron 1 mg PO twice daily) was administered daily 1 hour before and 8 hours after each satraplatin dose. A placebo antiemetic was administered in the placebo arm. Treatment continued until disease progression, unacceptable toxicity, patient withdrawal, noncompliance, or death. Crossover between treatment arms was not permitted.
To continue treatment, patients had to have an absolute neutrophil count Ն 1,500/L, platelets Ն 100,000/L, and nonhematologic toxicities attributed to study drug resolved to baseline or grade Յ 1 (except alopecia) or grade Յ 2 for pain. Satraplatin doses were delayed 1 week or decreased in the event of hematologic toxicity (absolute neutrophil count Յ 500/L, platelets Յ 25,000/L, or neutropenic fever) or GI toxicity (grade Ն 3 nausea, vomiting, or diarrhea); up to two dose delays or reductions of satraplatin were allowed (80 to 60 mg/m 2 and 60 to 40 mg/m 2 ). Dose escalation to 100 mg/m 2 was allowed for patients without progression and without substantial toxicity after two cycles of study drug. One dose reduction of prednisone to 5 mg once daily was allowed for grade Ն 3 hyperglycemia or other prednisonerelated toxicity.
Efficacy End Points
Primary end points were PFS and OS. PFS was a composite end point based on first occurrence of tumor progression, skeletal-related events, symptomatic progression, or death from any cause ( Table 1) . Increase in PSA was not a component of PFS. OS was defined as time from random assignment to death from any cause. Alternatively, patients were censored at time of last follow-up. Time to pain progression (TPP) was a secondary end point and was calculated from time from random assignment to date of pain progression. Pain progression required an increase in weekly average PPI score of Ն 1 point from baseline or Ն 2 points from nadir for Ն 2 consecutive weeks or a more than 25% increase from baseline in weekly average analgesic score for Ն 2 consecutive weeks. 16 Tumor response, PSA response, and pain response were prespecified exploratory end points. Tumor response and tumor response duration were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. 18 PSA response and PSA response duration used the Bubley criteria.
19 Pain response required a Ն 2-point reduction in weekly PPI score from baseline if baseline PPI score was Ն 2 or complete pain loss if baseline PPI score was less than 2, with no analgesic score increase for Ն 5 consecutive weeks.
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Assessments
All patients were reviewed blindly by an independent review committee (IRC) of radiologists and medical oncologists. All PFS and tumor response analyses were based on IRC assessment. Bone scans were conducted at baseline and after every two cycles for the first six treatment cycles, every three cycles until 12 treatment cycles, and every six cycles thereafter until progression. At baseline, computed tomography/magnetic resonance imaging scans of the abdomen/pelvis and chest x-ray/computed tomography scans were conducted. If metastatic disease was detected, scans were repeated every two cycles until progression. If not, scans were conducted at the investigator's discretion. Patients recorded pain scores and analgesic use in daily diaries. Disease-related pain was recorded using the PPI scale of the McGill-Melzack questionnaire validated for cancer pain assessment.
17, 21 Blinded review of diaries was performed by two independent scorers who calculated baseline and average weekly PPI and analgesic scores for each patient. Body weight and ECOG PS were assessed at baseline and before each treatment cycle.
Safety was evaluated for patients who received any study medication. Evaluations included incidence, type, and severity of adverse events (AEs), treatment-emergent AEs (TEAEs), and serious AEs (SAEs) and changes in vital signs or laboratory values. A TEAE was any event absent before treatment initiation or any existing event that worsened in intensity or frequency during treatment. Drug-related toxicity was assessed using the National Cancer Institute Common Toxicity Criteria version 2.0.
22
Statistical Design
The trial was designed to have 90% power to detect a 30% increase in time to median OS of 12 months in the placebo arm at a two-sided P ϭ .05. Assuming an accrual period of 24 months and follow-up time of 12 months, considering a 2:1 random assignment, 912 patients were to be accrued to observe 700 OS events within the 36-month study period. Similarly, 694 events were required for the PFS end point to provide a 30% improvement in HR at two-sided P ϭ .05 and 90% power.
Overall ␣ was adjusted for multiple comparisons of PFS and OS based on Hochberg-Tamhane and O'Brien-Fleming adjustments. 23, 24 Final OS and PFS analyses were tested at ␣ ϭ .0444 and ␣ ϭ .0244, respectively (Appendix).
Data Analysis
Efficacy analyses were based on the intent-to-treat (ITT) population. Safety analyses included all patients receiving any study drug. Time-to-event variables were assessed using Kaplan-Meier estimates analyzed using the logrank and Cox proportional hazard tests. Medians, HRs, 95% CIs, and P values were estimated using the following models: without stratification factors; with stratification factors (baseline PPI, PS, and type of disease progression after first-line chemotherapy); and with stratification factors and those prognostic factors found to be statistically significant (LDH, hemoglobin, ALP, and prior docetaxel; Appendix). Fisher's exact test compared response rates and AEs. All P values were from two-sided tests. All of these analyses were incorporated in the statistical analysis plan before unblinding the trial. A post hoc interactive model using indicator variables examined the potential interaction effects between study treatments and prior docetaxel. 
RESULTS
Patient Disposition
From September 2003 to January 2006, 950 patients (n ϭ 635, satraplatin; n ϭ 315, placebo) were enrolled at 170 sites in 16 countries. Patient demographics and baseline characteristics were balanced between treatment groups (Table 2 ). Figure 1 shows patient disposition.
Treatment
Drug exposure was greater in the satraplatin group, with a median of four treatment cycles (range, one to 34 cycles) and treatment duration of 20.0 weeks versus two cycles (range, one to 22 cycles) and treatment duration of 10.1 weeks in the placebo group. Median relative dose-intensity compared with planned dose was 95.5% for satraplatin and 97.8% for placebo. Dose reductions were 20.8% in the satraplatin arm and 0.3% in the placebo arm. Dose delays of Ն 7 days occurred in 41.7% and 10.5% of the satraplatin and placebo arms, respectively. Most discontinuations were a result of investigatordetermined progressive disease (719 of 950 overall discontinuations; 75.7%) and were balanced between groups.
Poststudy anticancer treatment was received by 61.7% of satraplatin patients (392 of 635 patients) and 68.6% of placebo patients (216 of 315 patients). Poststudy chemotherapy was received by 44.9% of satraplatin patients and 52.4% of placebo patients. Retrospective data collection determined that, of patients who received any poststudy chemotherapy, 138 (48.6%) of 284 patients in the satraplatin arm and 85 (51.5%) of 165 patients in the placebo arm received poststudy docetaxel.
Primary End Point of PFS
Median duration of postprogression follow-up was 29 weeks (range, 1 to 178 weeks) and 39 weeks (range, 0.3 to 157 weeks) in the satraplatin and placebo arms, respectively. The final IRC analysis of PFS data in the ITT population is based on 802 events, exceeding the planned goal of 700 events as a result of an underestimation in the number of subsequently determined IRC-defined PFS events. All 802 PFS events are discussed here to avoid bias. The Appendix includes a separate analysis based on the first 700 PFS events.
Median PFS was 11.1 weeks (95% CI, 10.3 to 12.3 weeks) in the satraplatin arm and 9.7 weeks (95% CI, 9.3 to 10.0 weeks) in the placebo arm (log-rank test, P Ͻ .001). Observed HR for progression or death was 0.67 for satraplatin versus placebo (95% CI, 0.57 to 0.77; P Ͻ .001; Fig 2A) .
There were 528 PFS events in the satraplatin arm and 274 PFS events in the placebo arm. PFS events in the satraplatin and placebo arms, respectively, were as follows: radiologic progression (35.8%, n ϭ 189 v 36.9%, n ϭ101), pain progression (34.3%, n ϭ 181 v 42.7%, n ϭ 117), skeletal-related events (4.2%, n ϭ 22 v 1.8%, n ϭ 5), no progression until death (9.1%, n ϭ 48 v 4.7%, n ϭ 13), and other symptomatic progression (16.6%, n ϭ 88 v 13.9%, n ϭ 38). Cox proportional hazards models revealed a significant (P Ͻ .001) 33% reduction in risk of progression or death favoring satraplatin versus placebo (HR ϭ 0.67; 95% CI, 0.57 to 0.77; Fig 2A) . A similar PFS effect was noted for docetaxel-pretreated patients (satraplatin, n ϭ 327; placebo, n ϭ 161; median PFS, 10.1 v 9.1 weeks; HR ϭ 0.67; 95% CI, 0.54 to 0.83). Figure 3A shows HRs for PFS in the ITT population and in various subsets. Several sensitivity analyses were performed, and these showed significant (P Յ .005) treatment effects of similar magnitude for each sensitivity analysis, supporting the overall robustness of the treatment effect (Appendix). Additionally, a post hoc Cox proportional hazard model examining interaction of treatment (satraplatin v placebo) and prior docetaxel (yes v no) showed a significant treatment effect, but the interaction effect was not significant (Appendix).
Primary End Point of OS
Of the 713 deaths, 474 and 239 deaths occurred in the satraplatin and placebo groups, respectively. Median OS for the stratified ITT analysis was 61.3 weeks for satraplatin and 61.4 weeks for placebo (HR ϭ 0.98; 95% CI, 0.84 to 1.15; P ϭ .80; Fig 2B) . In multivariate analyses adjusting for LDH, hemoglobin, and ALP (identified as significant [P Ͻ .001] prognostic factors in the Cox model; Appendix), HR for death was 0.88 (95% CI, 0.74 to 1.03; Fig 3B) . In docetaxelpretreated patients, median OS was 66.1 v 62.9 weeks in satraplatin and placebo arms, respectively (HR ϭ 0.91; 95% CI, 0.72 to 1.14). The same adjusted OS analysis in the docetaxel-pretreated patients showed an HR of 0.78 (95% CI, 0.61 to 0.99). A model with interaction term resulted in a trend toward statistical significance (P ϭ .06) but only when all stratification factors and significant prognostic factors were included in the Cox model (Appendix).
Secondary End Point of TPP
Median TPP in the ITT population favored satraplatin over placebo (66.1 v 22.3 weeks, respectively). There was a 36% reduction in the risk of pain progression with satraplatin therapy (HR ϭ 0.64; 95% CI, 0.51 to 0.79; P Ͻ .001). Because a log-rank test may overestimate median differences in the presence of censoring, an additional analysis of competing risk was performed, 29 which also favored satraplatin (K-sample, P ϭ .0015). PSA responses were observed in 25.4% and 12.4% of patients in the satraplatin and placebo arms, respectively (P Ͻ .001). Median duration of PSA response was 44.1 v 42.9 weeks in the satraplatin and placebo arms, respectively.
Exploratory End Points
Safety
The safety population comprised 942 patients (satraplatin, n ϭ 629; placebo, n ϭ 313). Most patients experienced one or more TEAE (satraplatin, 91.7% [577 of 629 patients]; placebo, 82.1% [257 of 313 patients]; P Ͻ .001). Table 3 lists all TEAEs (all grades and grades 3 and 4) occurring in more than 10% of patients in either group. Hematologic toxicities were the major dose-limiting toxicity in the satraplatin group and occurred at a higher incidence (P Ͻ .05) than in the placebo group. GI disorders were the most frequent nonhematologic TEAEs in the satraplatin group, occurring at a higher incidence (P Ͻ .001) than with placebo. TEAEs leading to discontinuation of study drug were more common with satraplatin than with placebo (14.9% v 10.2%, respectively). No significant differences were observed between the satraplatin and placebo arms in the incidence (any grade) of treatment-emergent hepatic toxicity (5.9% v 4.2%, respectively), renal toxicity (3.3% v 2.9%, respectively), or neuropathy (9.4% v 8.3%, respectively).
The incidence of SAEs (all grades, including death within 30 days of last dose) was higher in the satraplatin arm compared with the placebo arm (8.7% v 2.9% of patients, respectively; P Ͻ .001). Death within 30 days of last dose was similar between the two arms at 2.7% in the satraplatin arm and 2.9% in the placebo arm. The incidence of grade 3 or 4 SAEs was 6.2% in the satraplatin arm and 2.2% in the placebo arm (P Ͻ .05).
DISCUSSION
Median survival time in patients with metastatic CRPC has been reported to be 12 to 19 months.
2,3,30,31 Patients often have severe symptoms, including substantial pain from bone metastases, worsening functional status, and/or fatigue. Chemotherapy has gained greater acceptance with the demonstrated survival benefit of docetaxel.
In this phase III SPARC trial, satraplatin prolonged PFS in patients whose disease had progressed after prior chemotherapy, with the HR of 0.67 translating into a 33% reduction in PFS compared with placebo. The effect of satraplatin on PFS occurred across all prespecified patient subsets and was still apparent after 1 year. Although the difference in median PFS durations was numerically small, the corresponding CIs do not overlap, confirming that the observed effect is not a result of influential observations. Furthermore, given that the difference in medians represents only one point on the PFS curve (whereas overall treatment effect is meant to represent the overall difference between two groups), treatment benefits can be more completely evaluated by performing additional between-group comparisons (eg, 6 and 12 months after random assignment). In the present trial, estimated PFS rates at 6 months for the satraplatin and placebo groups were 30% and 17%, respectively; corresponding 1-year PFS rates were 16% and 7%, respectively.
The composite PFS end point incorporated clinically relevant and objective measures of disease progression and functional status, including those recommended by the Prostate Cancer Working Group, 32 and was similar to a PFS measure predictive for OS in advanced prostate cancer. 33 Standard PFS measures may not provide accurate assessments of the true time of disease progression in part because of interval assessment bias. 33, 34 This composite PFS reduces the risk of missing disease recurrence because it encompasses tumor progression, skeletal events, symptomatic progression, and/or death.
When the trial commenced in 2003, docetaxel was not the standard of care for CRPC, so not all patients received docetaxel as firstline chemotherapy. Although this trial did not demonstrate a survival benefit for the overall population, a prespecified analysis of docetaxel-pretreated patients demonstrated improved OS with satraplatin when the analysis was adjusted for significant prespecified prognostic factors.
Satraplatin had beneficial effects on TPP and on tumor response, pain response, and PSA response. A quality-of-life assessment was not part of the trial, but satraplatin showed a positive effect on pain progression and pain response.
Satraplatin was generally well tolerated in this elderly population with metastatic disease and prior chemotherapy treatment. The AE profile was similar to that in the previous satraplatin study in chemotherapy-naïve patients with CRPC. 16 Hematologic toxicities were higher in the satraplatin group. Nonhematologic toxicities were mostly low grade. In contrast to other platinum analogs, no significant worsening of renal function or neuropathy occurred with satraplatin.
In conclusion, orally administered satraplatin was well tolerated in patients with advanced CRPC, with beneficial effects on disease progression and pain. The effect on PFS was numerically small yet statistically significant in favor of satraplatin and occurred across all subgroups (including docetaxel-pretreated patients), which is important because docetaxel has become first-line therapy of choice and CRPC is a heterogeneous disease. Satraplatin did not demonstrate a survival benefit in this study, but its effect on pain and pain progression should be noted in this patient population who suffer from painful bone metastases. Satraplatin chemotherapy may potentially address an unmet need in patients with CRPC whose disease progressed after initial chemotherapy. Confirmatory trials are needed to establish the true role of satraplatin in advanced prostate cancer. 
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